KLI

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

Metadata Downloads
Publisher
Esmo Open
Language
영어
ISSN
2059-7029
Citation Volume
5
Citation Number
4
Citation Start Page
000714
Citation End Page
000714
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.